How Fitness and Wellness Companies Are Successfully Integrating GLP-1 Medications

Strategic Adaptations in the Wellness Industry

Major fitness and wellness companies are taking calculated approaches to incorporate weight-loss medications like Ozempic and Wegovy into their business models, deliberately avoiding the difficulties that WW International (formerly Weight Watchers) experienced during its transition.

These corporations, including Noom, Hims & Hers Health, and Life Time Group Holdings, have been carefully observing WW’s challenging journey as it attempted to pivot its decades-old weight management program to embrace the new pharmaceutical options.

“We’ve been actually been pretty fortunate that we’ve been able to kind of watch what has happened with Weight Watchers,” said Noom Chief Executive Geoff Cook during a recent earnings call.

WW’s Challenging Transition Period

WW International encountered significant hurdles after acquiring telehealth platform Sequence in March 2023, a move designed to provide members access to weight-loss medications. The company struggled with the integration, facing operational challenges that contributed to disappointing financial results.

These difficulties ultimately led to the departure of Sima Sistani as CEO in May after just two years in the position. The company also reported a concerning 7.3% decline in subscribers during its first quarter.

WW’s stock has plummeted approximately 75% since the acquisition announcement, highlighting the complex challenges of incorporating pharmaceutical solutions into established behavior-based weight management programs.

Successful Integration Models Emerging

In contrast, several companies have managed the integration more effectively. Hims & Hers Health has seen its shares surge over 130% this year after successfully incorporating GLP-1 medications into its telehealth offerings. The company reported its first profitable quarter in May.

Meanwhile, Life Time Group, which operates high-end fitness centers, has approached the trend differently by introducing a medical weight management program that combines GLP-1 drugs with personalized coaching and medical oversight, directly addressing customer interest in these medications.

“We have seen an increase in demand related to people needing additional support with those medications,” said Life Time Chief Operating Officer Jeff Zwiefel in an interview.

Market Dynamics and Future Outlook

The expanding market for weight loss medications continues to transform the health and wellness landscape. Analysts from Morgan Stanley project this market could reach $77 billion by 2030, creating both challenges and opportunities for established weight management companies.

The key differentiator appears to be how seamlessly companies can integrate these medications into their existing frameworks while maintaining their core value propositions. Those offering comprehensive support systems alongside medication access seem better positioned for success.

Noom, for instance, emphasizes that its psychology-based approach provides essential support for medication users, helping them maintain weight loss and develop sustainable habits.

“It’s very clear people don’t want just the medication,” Cook said. “They want the medication with behavior change support.”

As these medications become increasingly mainstream, wellness companies that can effectively blend pharmaceutical solutions with behavioral support and lifestyle guidance appear best positioned to thrive in this evolving market.